Karyopharm shares tank after FDA insiders slam their case on the efficacy of a cancer drug with “significant toxicity”
Karyopharm’s attempt to gain an accelerated approved for selinexor as a treatment for drug-resistant cases of multiple myeloma is in serious jeopardy. And investors know it.
Given the history of the FDA with these kinds of reviews, Tuesday’s assessment will likely be harsh.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.